Travere Therapeutics
San Diego, California, United States · Biotechnology, Health Care, Pharmaceutical
Travere Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for people living with rare diseases. It specializes in addressing unmet medical needs associated with kidney diseases. The company aims to improve treatment outcomes for patients through scientific advancements and breakthroughs in drug development.
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 550
- Industries
- Biotechnology, Health Care, Pharmaceutical
- Status
- Public (TVTX)
- Website
- travere.com
- Company page
Recent activity at Travere Therapeutics
- : Travere Therapeutics Appoints Bradley L. Campbell as Chief Executive Officer
- : Travere Therapeutics Enters License Agreement with Everest Medicines (date Fundz recorded it)
- : SEC 8-K (5.02): On September 21, 2026, Travere Therapeutics, Inc. announced the planned departure of Dr. Eric Dube as President and CEO, effective December 1, 2026. Dr. Dube will also step down from the Board of Directors but will remain as an Executive Advisor until February 15, 2027, to ensure a smooth transition. Bradley L. Campbell has been appointed as his successor, effective on the same date. Mr. Campbell brings over 25 years of biopharmaceutical experience, previously serving as CEO of Amicus Therapeutics until its acquisition in April 2026. This transition may impact the strategic direction of the company as new leadership is introduced.
- : SEC 8-K (5.02): On July 6, 2026, Sandra Calvin, the chief accounting officer (CAO) and principal accounting officer (PAO) of the Company, announced her intention to retire, with the expected date being following the filing of the Company’s Annual Report on Form 10-K in February 2027. John Torell, currently the Vice President and Controller, is anticipated to succeed Ms. Calvin. The Board plans to appoint Mr. Torell to these roles prior to the Retirement Date to ensure a smooth transition of responsibilities. Mr. Torell, a Chartered Financial Analyst and Certified Public Accountant, has extensive experience in various financial roles, enhancing the Company's leadership continuity in accounting operations and financial reporting.
- : SEC 8-K (5.02):
- : SEC 8-K (1.01): On June 1, 2026, Travere Therapeutics, Inc. entered into a material license and collaboration agreement with Everest Medicines (Singapore) Pte. Ltd. The Agreement provides Travere an exclusive, royalty-bearing license to develop and commercialize civorebrutinib, a Bruton’s tyrosine kinase inhibitor, for use in various diseases outside of China and certain East and Southeast Asian countries. Travere will also collaborate with Everest on global clinical trials while assuming responsibility for commercialization in the designated territory. Key financial details include an upfront payment from Travere and provisions for cost-sharing in development. The strategic impact involves enhancing Travere's portfolio in the biotech domain, leveraging Everest's resources and intellectual property for successful product exploitation.
- : SEC 8-K (1.01): On June 1, 2026, Travere Therapeutics, Inc. entered into a license and collaboration agreement with Everest Medicines (Singapore) Pte. Ltd. This Agreement grants Travere an exclusive license for the development and commercialization of civorebrutinib, a Bruton’s tyrosine kinase inhibitor, across all countries outside of China and specific territories in East and Southeast Asia. The Company will receive a royalty-bearing license and the right to grant sublicenses under Everest's patents and know-how. This strategic partnership aims to enhance Travere's portfolio in the treatment of various diseases and disorders, reflecting the company's intent to expand its therapeutic capabilities significantly.
- : SEC 8-K (5.02): On May 19, 2026, Travere Therapeutics, Inc. conducted its Annual Meeting of Stockholders where significant corporate governance changes occurred. The stockholders elected ten directors to serve until the 2027 Annual Meeting, with Roy D. Baynes, M.D., Ph.D., receiving 66,479,999 votes in favor. Additionally, they approved amendments to the 2018 Equity Incentive Plan, increasing the shares of common stock authorized for issuance by 3,000,000 shares, with 72,998,395 votes in favor. The meeting reflected strong engagement from stockholders with 81,108,473 shares present, showcasing active participation in the company's governance process.
- : SEC 8-K (5.02): On May 19, 2026, Travere Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders, where stockholders approved an amendment to the Company’s 2018 Equity Incentive Plan, increasing the number of shares authorized for issuance by 3,000,000 shares. This change is significant for the Company as it may enhance its ability to attract and retain talent through equity compensation. The approval reflects on the Company's plans for growth and potential expansion of its workforce. The specific terms of the 2018 Plan were detailed in the proxy statement filed on April 6, 2026.
- : SEC 8-K (1.01): On May 11, 2026, Travere Therapeutics, Inc. completed a registered underwritten public offering of $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032. The offering was facilitated by J.P. Morgan Securities LLC, Jefferies LLC, and Leerink Partners LLC as underwriters, with an additional $50.0 million sold to cover over-allotments. The Notes will mature on May 15, 2032, and will bear an annual interest rate of 0.50%, paid semi-annually starting November 15, 2026. This offering, registered under the Securities Act, indicates the company's strategic move to strengthen its capital structure and provide financial flexibility for future endeavors.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Leadership
- Eric Dube, CEO
- Bradley L. Campbell, Chief Executive Officer
Verified email and direct lines for Travere Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Travere Therapeutics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Travere Therapeutics in the news
- Travere Therapeutics to Report Third Quarter 2026 Financial Results - Yahoo Finance (Oct 26, 2026)
- U.S. FDA approves Travere Therapeutics kidney disorder drug - Reuters (Feb 17, 2023)
- Travere Therapeutics to Participate at Upcoming Investor Conferences - Yahoo Finance (Nov 03, 2026)
- Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day - Business Wire (Jun 10, 2025)
- Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum - Yahoo Finance (Sep 17, 2026)
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance (Jul 10, 2026)
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance (Aug 12, 2026)
- Travere Therapeutics, Inc. (TVTX) Company Profile & Facts - Yahoo Finance - Yahoo! Finance Canada (Apr 04, 2021)
Companies similar to Travere Therapeutics
- Acadia Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Arcus Biosciences · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Madrigal Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Crinetics Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Apellis Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Travere Therapeutics: questions and answers
What does Travere Therapeutics do?
Travere Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for people living with rare diseases. It specializes in addressing unmet medical needs associated with kidney diseases. The company aims to improve treatment outcomes for patients through scientific advancements and breakthroughs in drug development.
Where is Travere Therapeutics headquartered?
Travere Therapeutics is headquartered in San Diego, California, United States.
How many employees does Travere Therapeutics have?
Travere Therapeutics has about 550 employees.
Who leads Travere Therapeutics?
Eric Dube is a CEO at Travere Therapeutics.
What is the latest news on Travere Therapeutics?
On Sep 21, 2026, Travere Therapeutics Appoints Bradley L. Campbell as Chief Executive Officer
Is Travere Therapeutics a public company?
Yes. Travere Therapeutics is publicly traded under the ticker TVTX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy